Karuna Therapeutics (NASDAQ:KRTX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Karuna Therapeutics (NASDAQ:KRTX – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $300.00 target price on the stock. Several other research firms also recently weighed in on KRTX. Cantor Fitzgerald reiterated a neutral rating and […]

Related Keywords

United States ,America ,Jeffreym Jonas ,Troya Ignelzi , ,Financial Services Group Inc ,Karuna Therapeutics Company Profile ,Lazard Asset Management ,Morgan Stanley ,Exchange Traded Concepts ,Almanack Investment Partners ,Cantor Fitzgerald ,First Horizon Advisors Inc ,Karuna Therapeutics Inc ,Securities Exchange Commission ,Wells Fargo Company ,Karuna Therapeutics ,Free Report ,Moderate Buy ,Therapeutics Stock Down ,Get Free Report ,Director Jeffrey ,Exchange Commission ,Horizon Advisors ,Services Group ,Asset Management ,Investment Partners ,Karuna Therapeutics Daily ,Nasdaq Krtx ,Krtx ,Medical ,Reiterated Rating ,Hc Wainwright ,